Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.
A user had a bad reaction to Finasteride, experiencing anxiety and fatigue, and is seeking alternative hair loss treatments since they can't use Finasteride or Minoxidil. Suggestions include trying low doses of Finasteride, making a topical version, or using other treatments like Alfatradiol, but the user is hesitant to use Finasteride again and is considering a hair transplant.
User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hairfollicles for better treatment.
Stopping microneedling may result in losing hair gains, as it enhances the effectiveness of treatments like minoxidil. Combining microneedling with minoxidil and finasteride is more effective than using microneedling alone.
The conversation is about the role of vitamin deficiencies in hair loss and the effectiveness of treatments like Minoxidil, finasteride, and RU58841. It concludes that while vitamins and nutrition are important, they are not the primary solution for androgenic alopecia.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hairfollicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
Scalp tension from the occipitalis muscle is theorized to contribute to hair loss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.
A new serum claims to enhance hair regrowth by amplifying oxygen delivery, improving the effectiveness of treatments like exosomes and peptides. Users are skeptical, questioning its efficacy compared to established treatments like Minoxidil and Finasteride.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hairfollicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
PP405 is a potential hair loss treatment that may work by blocking signals that cause haircells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
A product that makes hair look thicker and healthier without promoting regrowth. Discussions include treatments like minoxidil, finasteride, red light therapy, and a serum with caffeine and peptides, with mixed effectiveness opinions.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hairfollicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
The user discusses using dutasteride to stop hair loss and bimatoprost for regrowth. They plan to use VEGF with hydrogels for potentially permanent hairfollicle improvement and suggest PRP as an alternative.
The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
People are hopeful for a permanent hair loss solution by the 2030s, considering options likehair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.
Users discussed using treatments like minoxidil, finasteride, dutasteride, and exosomes for hair loss. They reported thicker hair and reduced shedding, with some experiencing minor side effects.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
A 26-year-old man from France started experiencing hair loss in September 2020 and began using finasteride in June 2021, reporting some improvement after three months without side effects. He plans to continue finasteride for a year before considering additional treatments like minoxidil or dermarolling.
The conversation lists hair loss treatments including finasteride, dutasteride, RU58841, pyrilutamide, breezula, and fluridil, and suggests ketoconazole as another option. Some users warn against using certain treatments like cyproterone acetate, bicalutamide, and spironolactone due to their strong anti-androgen effects and potential impact on masculinity.
A user is treating their advanced hair loss with a regimen including topical finasteride, minoxidil, hydrocortisone, stem cell serum, peptide serum, multivitamins, he shou wu tea, derma pen, argan oil, and a derma roller. Replies suggest it's too early to judge progress and recommend staying consistent, with one suggesting oral minoxidil as an additional option.
The conversation is about hair loss treatments, specifically using dutasteride and oral minoxidil, and exploring additional vitamins and supplements like vitamin D, zinc, biotin, and omega-3 to support hair health. Users suggest getting a blood panel to identify deficiencies and emphasize the importance of protein and overall nutrition.
Insulin resistance may increase DHT production, contributing to hair loss, and addressing it through diet, nutrients, and natural DHT blockers like saw palmetto and pumpkin seed oil could help reverse hair loss. Some users prefer medications like finasteride for more effective results.
Microneedling, combined with finasteride and minoxidil, appears to enhance hair growth, with users reporting noticeable improvements. The process involves using a 0.5mm derma roller, which some believe increases blood flow and stimulates hairfollicles.
Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hairfollicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.
Treatments for hair loss, including finasteride, dutasteride, minoxidil, ketoconazole, microneedling, and low level laser light therapy, which aim to reduce DHT production, increase cell absorption and blood flow, and stimulate epidermal stem cells. It also stresses the importance of patience when using these treatments.
There is no permanent cure for hair loss; treatments like finasteride, minoxidil, and hair transplants require ongoing use and are not universally effective. Genetic complexity and financial incentives for ongoing treatments hinder the development of a definitive cure.